รศ.(พิเศษ).พญ.อนุสสรา ประยงค์รัตน์
แพทย์รังสีรักษา
ABOUT DR. PRAYONGRAT
Dr.Prayongrat is an attending staff at Division of Radiation Oncology, King Chulalongkorn Memorial Hospital, and a lecturer of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University. She specializes on the radiation treatment for CNS tumors, head and neck cancers, and gastrointestinal cancers using advance radiation techniques including intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic radiosurgery/radiotherapy (SRS/SRT), and proton therapy. Her research interest involves clinical research on advance radiotherapy and predictive modelling for tumor control and radiation toxicity by the integration of clinical data, dosiomics, and radiomics. Dr.Prayongrat is the co-investigator of a multi-institutional Phase II/III randomized trial that compares outcomes of IMRT versus IMPT in esophageal cancer.
ประวัติ
- 2546-2552: แพทยศาสตร์บัณฑิต (เกียรตินิยมอันดับหนึ่ง เหรียญทอง) จุฬาลงกรณ์มหาวิทยาลัย
- 2553-2556: วุฒิบัตรแสดงความรู้ความชำนาญในการประกอบวิชาชีพเวชกรรมสาขารังสีรักษา
- 2559-2560: Visiting scientist in Stereotactic Radiosurgery and Proton Therapy The University of Texas MD Anderson Cancer Center, U.S.A.
- 2561-2563: Doctoral of Philosophy, Graduate School of Medicine, Hokkaido University, Japan
- 2553-2554: แพทย์เพิ่มพูนทักษะ โรงพยาบาลสมเด็จพระนางเจ้าสิริกิติ์ พร. จ.ชลบุรี
- 2554-2556: แพทย์ประจำบ้านสาขารังสีรักษาและมะเร็งวิทยา โรงพยาบาลจุฬาลงกรณ์
- 2556-ปัจจุบัน: แพทย์รังสีรักษาและมะเร็งวิทยา โรงพยาบาลจุฬาลงกรณ์
Hypothyroidism after radiotherapy for nasopharyngeal carcinoma. Anussara Prayongrat, Chawalit Lertbutsayanukul. Ann Nasopharynx Cancer 2020;4:3 | http://dx.doi.org/10.21037/anpc.2020.03.03
Long-term patient-rated cosmetic and satisfactory outcomes of early breast cancer treated with conventional versus hypofractionated breast irradiation with simultaneous integrated boost technique. Lertbutsayanukul C, Pitak M, Ajchariyasongkram N, Rakkiet N, Seuree F, Prayongrat A. Breast J. 2020 Jul 9. doi: 10.1111/tbj.13960.
Nishioka K, Prayongrat A, Ono K, Onodera S, Hashimoto T, Katoh N, Inoue T, Kinoshita R, Yasuda K, Mori T, Onimaru R, Shirato H, Shimizu S.Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system. J Radiat Res. 2018;59(suppl_1):i63-71.
Lertbutsayanukul C, Prayongrat A, Kannarunimit D, Chakkabat C, Netsawang B, Kitpanit S. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlenther Onkol. 2018;194(5):375-85.
Prayongrat A, Xu C, Li H, Lin SH. Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv Radiat Oncol. 2017;2(3):301-7.
Prayongrat A, Tao R, Allen PK, Guha N, Rao G, Zhoa Z, Li J, Brown PD, Mcgovern S. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neuro-Oncology Practice. 2018. 5(1). 37–45.
Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer. 2017;8(3):219-28.
Lan M, Chen C, Huang Y, Tian L, Duan Z, Han F, Liao J, Deng M, Sio TT, Prayongrat A, Zheng L, Wu S, Lu T. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis. Sci Rep. 2017;7:42624.
Prayongrat A, Chakkabat C, Kannarunimit D, Hansasuta P, Lertbutsayanukul C. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma. J Radiat Res. 2017;58(4):509-16.
Songthong (Prayongrat) A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C. Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. Radiol Oncol. 2015; 49(2):155-62.
Songthong (Prayongrat) A, Kannarunimit D, Chakkabat C, Lertbutsayanukul C. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol. 2015;10:166.
Prayongrat A, Kobashi K, Ito YM, Katoh N, Tamura M, Dekura Y, Toramatsu C, Khorprasert C, Amornwichet A, Alisanant P, Shirato H, Shimizu S. The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. Radiother Oncol. 2019;135:100–6.
Johnstone G, Ghia A, Prayongrat A. External Beam Radiotherapy in the Treatment of Painful Bone Metastases. In: Gulati A, Puttanniah V, Bruel BM, Rosenberg WS, Hung JC editors. Essentials of Interventional Cancer Pain Management. Cham, Switzerland: Springer Nature; 2019. p. 339-52.
Ghia A, Prayongrat A. Vertebral body metastasis. In: Chang E, Brown PD, editors. Adult CNS Radiation Oncology: Principle and Practice. Cham, Switzerland: Springer International Publishing; 2018. p. 177-188.
Lertbutsayanukul C, Kannarunimit D, Prayongrat A, Chakkabat C, Kitpanit S, Hansasuta P. Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy. Radiol Oncol. 2018;52(2):195-203.
Lertbutsayanukul C, Kitpanit S, Prayongrat A, Kannarunimit D, Netsawang B, Chakkabat C. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. J Radiat Res. 2018 Jul 1;59(4):446-55.
Sio TT, Prayongrat A, Zhang Y, Lin Q, Xu T, Liao Z, Yue J. The Road Less Traveled: Should We Omit Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer? Clin Lung Cancer. 2018 Jul;19(4):289-93.
Kobashi K, Prayongrat A, Kimoto T, Toramatsu C, Dekura Y, Katoh N, Shimizu S, Ito YM, Shirato H. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. J Radiat Res. 2018 Mar 1;59(suppl_1):i50-7.
Prayongrat A, Umegaki K, van der Schaaf A, Koong AC, Lin SH, Whitaker T, McNutt T, Matsufuji N, Graves E, Mizuta M, Ogawa K, Date H, Moriwaki K, Ito YM, Kobashi K, Dekura Y, Shimizu S, Shirato H. Present developments in reaching an international consensus for a model-based approach to particle beam therapy. J Radiat Res. 2018;59(suppl_1):i72-6.
Lertbutsayanukul C, Kannarunimit D, Netsawang B, Kitpanit S, Chakkabat C, Hansasuta P, Prayongrat A. Optimal plasma pretreatment EBV DNA cut-off point for nasopharyngeal cancer patients treated with intensity modulated radiation therapy. Jpn J Clin Oncol. 2018;48(5):467-75.
Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, Giaccia A, Xing L, Umegaki K. Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res. 2018;59(suppl_1):i2-10.